Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome

Bibliographic Details
Title: Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in Sézary syndrome
Authors: Christoph Iselin, Yun-Tsan Chang, Tanja Schlaepfer, Christina Fassnacht, Florentia Dimitriou, Mirjam Nägeli, Steve Pascolo, Wolfram Hoetzenecker, Malgorzata Bobrowicz, Emmanuella Guenova
Source: OncoImmunology, Vol 10, Iss 1 (2021)
Publisher Information: Taylor & Francis Group, 2021.
Publication Year: 2021
Collection: LCC:Immunologic diseases. Allergy
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: cutaneous t cell lymphoma, sézary syndrome, mycosis fungoides, dermatology, extracorporeal photophoresis, cellular cytotoxicity, biomarker, treatment response, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Sézary syndrome (SS) is a rare, leukemic type of cutaneous T-cell lymphoma (CTCL), for which extracorporeal photopheresis (ECP) is a first-line therapy. Reliable biomarkers to objectively monitor the response to ECP in patients with SS are missing. We examined the quantitative and qualitative impact of ECP on natural killer (NK) cell activity in SS patients, and especially their functional ability for antibody-dependent cell-mediated cytotoxicity (ADCC). Further, we addressed the question whether the magnitude of the effect on ADCC can be associated with the anti-cancer efficacy of ECP in SS patients. We assessed numbers of NK cells, ADCC activity, and treatment response based on blood tumor staging in a cohort of 13 SS patients (8 women, 5 men) treated with ECP as a first-line therapy. Blood samples were collected before treatment start and after an average of 9 months of uninterrupted ECP treatment. NK cell numbers were reduced in SS patients compared to healthy individuals and showed a tendency of recovery after long-term ECP treatment, independent of the clinical response to treatment. Patients with marginal increase (≤1.5 AU-fold) or lack of increase in ADCC activity failed to respond clinically to treatment, while patients with an increased ADCC activity showed a reduction in blood tumor burden. NK-mediated ADCC is selectively enhanced and might be a mechanism underlying the effect of ECP while in addition it can possibly serve as a reliable biomarker to objectively monitor response to ECP in patients with SS.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2162-402X
2162402X
Relation: https://doaj.org/toc/2162-402X
DOI: 10.1080/2162402X.2021.1873530
Access URL: https://doaj.org/article/79be4c7424ec40aabeb2285e0800e27d
Accession Number: edsdoj.79be4c7424ec40aabeb2285e0800e27d
Database: Directory of Open Access Journals
More Details
ISSN:2162402X
DOI:10.1080/2162402X.2021.1873530
Published in:OncoImmunology
Language:English